Loading...
Please wait, while we are loading the content...
Similar Documents
CD73: an emerging checkpoint for cancer immunotherapy.
| Content Provider | Europe PMC |
|---|---|
| Author | Chen, Siqi Wainwright, Derek A Wu, Jennifer D Wan, Yong Matei, Daniela E Zhang, Yi Zhang, Bin |
| Copyright Year | 2019 |
| Abstract | CD73 is a novel immune checkpoint associated with adenosine metabolism that promotes tumor progression by suppressing antitumor immune response and promoting angiogenesis. The inhibition of CD73, in combination with immune checkpoint blockade, targeted therapy or conventional therapy, improves antitumor effects in numerous preclinical mouse models of cancer. Emerging evidence suggests that the combination of anti-CD73 and immune checkpoint blockade has promising clinical activity in patients with advanced solid tumors. In this review, we will discuss the specific role of CD73 on both tumor cells and nontumor cells in regulating tumor immunity and tumorigenesis and provide an update on the current view of the antitumor activity of targeting CD73 by mAb or small molecule selective inhibitors in preclinical and clinical settings. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6609898&blobtype=pdf |
| Page Count | 15 |
| ISSN | 1750743X |
| Volume Number | 11 |
| DOI | 10.2217/imt-2018-0200 |
| PubMed Central reference number | PMC6609898 |
| Issue Number | 11 |
| PubMed reference number | 31223045 |
| Journal | Immunotherapy |
| e-ISSN | 17507448 |
| Language | English |
| Publisher | Future Medicine Ltd |
| Publisher Date | 2019-06-21 |
| Publisher Place | London, UK |
| Access Restriction | Open |
| Rights License | © 2019 Future Medicine Ltd |
| Subject Keyword | adenosine receptor CD73 immune checkpoint blockade immunotherapy tumor evasion |
| Content Type | Text |
| Resource Type | Article |
| Subject | Immunology and Allergy Immunology Oncology |
